Breast cancer risk after exposure to fertility drugs

References

• Boivin J, Bunting L, Collins JA, Nygren KG. International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care. Hum. Reprod. 22(6), 1506–1512 (2007).
   PubMed Web of Science ®Google Scholar
• Mosher WD, Pratt WF. Fecundity and infertility in the United States: incidence and trends. Fertil. Steril. 56(2), 192–193 (1991).
   PubMed Web of Science ®Google Scholar
• Makar RS, Toth TL. The evaluation of infertility. Am. J. Clin. Pathol. 117(Suppl.), S95–103 (2002).
   PubMedGoogle Scholar
• Henne MB, Bundorf MK. Insurance mandates and trends in infertility treatments. Fertil. Steril. 89(1), 66–73 (2008).
   PubMed Web of Science ®Google Scholar
• Wysowski DK. Use of fertility drugs in the United States, 1973 through 1991. Fertil. Steril. 60(6), 1096–1098 (1993).
   PubMed Web of Science ®Google Scholar
• Practice Committee of the American Society for Reproductive Medicine. Use of clomiphene citrate in women. Fertil. Steril. 82(1), 90–96 (2004).
   Google Scholar
• Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J. Clin. Oncol. 14(5), 1718–1729 (1996).
   PubMed Web of Science ®Google Scholar
• Tomao F, Spinelli GP, Panici PB, Frati L, Tomao S. Ovarian function, reproduction and strategies for fertility preservation after breast cancer. Crit. Rev. Oncol. Hematol. 76(1), 1–12 (2010).
   PubMed Web of Science ®Google Scholar
• Lipworth L. Epidemiology of breast cancer. Eur. J. Cancer Prev. 4(1), 7–30 (1995).
   PubMed Web of Science ®Google Scholar
• Bernstein L. Epidemiology of endocrine-related risk factors for breast cancer. J. Mammary Gland Biol. Neoplasia 7(1), 3–15 (2002).
   PubMed Web of Science ®Google Scholar
• Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol. 2(3), 133–140 (2001).
   PubMed Web of Science ®Google Scholar
• Madigan MP, Ziegler RG, Benichou J, Byrne C, Hoover RN. Proportion of breast cancer cases in the United States explained by well-established risk factors. J. Natl. Cancer Inst. 87(22), 1681–1685 (1995).
   PubMed Web of Science ®Google Scholar
• Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol. Rev. 15(1), 36–47 (1993).
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 347(9017), 1713–1727 (1996).
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350(9084), 1047–1059 (1997).
   PubMed Web of Science ®Google Scholar
• Kotsopoulos J, Librach CL, Lubinski J et al.; Hereditary Breast Cancer Clinical Study Group. Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case–control study. Cancer Causes Control 19(10), 1111–1119 (2008).
   PubMed Web of Science ®Google Scholar
• Gauthier E, Paoletti X, Clavel-Chapelon F; E3N group. Breast cancer risk associated with being treated for infertility: results from the French E3N cohort study. Hum. Reprod. 19(10), 2216–2221 (2004).
   PubMed Web of Science ®Google Scholar
• Doyle P, Maconochie N, Beral V, Swerdlow AJ, Tan SL. Cancer incidence following treatment for infertility at a clinic in the UK. Hum. Reprod. 17(8), 2209–2213 (2002).
   PubMed Web of Science ®Google Scholar
• Potashnik G, Lerner-Geva L, Genkin L, Chetrit A, Lunenfeld E, Porath A. Fertility drugs and the risk of breast and ovarian cancers: results of a long-term follow-up study. Fertil. Steril. 71(5), 853–859 (1999).
   PubMed Web of Science ®Google Scholar
• Silva Idos S, Wark PA, McCormack VA et al. Ovulation-stimulation drugs and cancer risks: a long-term follow-up of a British cohort. Br. J. Cancer 100(11), 1824–1831 (2009).
   PubMed Web of Science ®Google Scholar
• Braga C, Negri E, La Vecchia C, Parazzini F, Dal Maso L, Franceschi S. Fertility treatment and risk of breast cancer. Hum. Reprod. 11(2), 300–303 (1996).
   PubMed Web of Science ®Google Scholar
• Modan B, Ron E, Lerner-Geva L et al. Cancer incidence in a cohort of infertile women. Am. J. Epidemiol. 147(11), 1038–1042 (1998).
   PubMed Web of Science ®Google Scholar
• Ricci E, Parazzini F, Negri E, Marsico S, La Vecchia C. Fertility drugs and the risk of breast cancer. Hum. Reprod. 14(6), 1653–1655 (1999).
   PubMed Web of Science ®Google Scholar
• Bernstein L, Hanisch R, Sullivan-Halley J, Ross RK. Treatment with human chorionic gonadotropin and risk of breast cancer. Cancer Epidemiol. Biomarkers Prev. 4(5), 437–440 (1995).
   PubMed Web of Science ®Google Scholar
• Jensen A, Sharif H, Svare EI, Frederiksen K, Kjaer SK. Risk of breast cancer after exposure to fertility drugs: results from a large Danish cohort study. Cancer Epidemiol. Biomarkers Prev. 16(7), 1400–1407 (2007).
   PubMed Web of Science ®Google Scholar
• Burkman RT, Tang MT, Malone KE et al. Infertility drugs and the risk of breast cancer: findings from the National Institute of Child Health and Human Development Women’s Contraceptive and Reproductive Experiences Study. Fertil. Steril. 79(4), 844–851 (2003).
   PubMed Web of Science ®Google Scholar
• Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Risk of breast cancer in a cohort of infertile women. Gynecol. Oncol. 60(1), 3–7 (1996).
   PubMed Web of Science ®Google Scholar
• Terry KL, Willett WC, Rich-Edwards JW, Michels KB. A prospective study of infertility due to ovulatory disorders, ovulation induction, and incidence of breast cancer. Arch. Intern. Med. 166(22), 2484–2489 (2006).
   PubMedGoogle Scholar
• Brinton LA, Scoccia B, Moghissi KS et al. Breast cancer risk associated with ovulation-stimulating drugs. Hum. Reprod. 19(9), 2005–2013 (2004).
   PubMed Web of Science ®Google Scholar
• Lerner-Geva L, Keinan-Boker L, Blumstein T et al. Infertility, ovulation induction treatments and the incidence of breast cancer – a historical prospective cohort of Israeli women. Breast Cancer Res. Treat. 100(2), 201–212 (2006).
   PubMed Web of Science ®Google Scholar
• Calderon-Margalit R, Friedlander Y, Yanetz R et al. Cancer risk after exposure to treatments for ovulation induction. Am. J. Epidemiol. 169(3), 365–375 (2009).
   PubMed Web of Science ®Google Scholar
• Orgéas CC, Sanner K, Hall P et al. Breast cancer incidence after hormonal infertility treatment in Sweden: a cohort study. Am. J. Obstet. Gynecol. 200(1), 72.e1–72.e7 (2009).
   Google Scholar
• Fei C, Deroo LA, Sandler DP, Weinberg CR. Fertility drugs and young-onset breast cancer: results from the Two Sister Study. J. Natl. Cancer Inst. 104(13), 1021–1027 (2012).
   PubMedGoogle Scholar
• Lerner-Geva L, Geva E, Lessing JB, Chetrit A, Modan B, Amit A. The possible association between in vitro fertilization treatments and cancer development. Int. J. Gynecol. Cancer 13(1), 23–27 (2003).
   PubMed Web of Science ®Google Scholar
• Dor J, Lerner-Geva L, Rabinovici J et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertil. Steril. 77(2), 324–327 (2002).
   PubMed Web of Science ®Google Scholar
• Venn A, Watson L, Bruinsma F, Giles G, Healy D. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet 354(9190), 1586–1590 (1999).
   PubMed Web of Science ®Google Scholar
• Brzezinski A, Peretz T, Mor-Yosef S, Schenker JG. Ovarian stimulation and breast cancer: is there a link? Gynecol. Oncol. 52(3), 292–295 (1994).
   PubMed Web of Science ®Google Scholar
• Venn A, Watson L, Lumley J, Giles G, King C, Healy D. Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet 346(8981), 995–1000 (1995).
   PubMed Web of Science ®Google Scholar
• Jourdain O, Avril A, Mauriac L et al. Breast cancer and in vitro fertilization. About 32 cases. Eur. J. Obstet. Gynecol. Reprod. Biol. 67(1), 47–52 (1996).
   PubMed Web of Science ®Google Scholar
• Kristiansson P, Björ O, Wramsby H. Tumour incidence in Swedish women who gave birth following IVF treatment. Hum. Reprod. 22(2), 421–426 (2007).
   PubMed Web of Science ®Google Scholar
• Katz D, Paltiel O, Peretz T et al. Beginning IVF treatments after age 30 increases the risk of breast cancer: results of a case–control study. Breast J. 14(6), 517–522 (2008).
   PubMed Web of Science ®Google Scholar
• Pappo I, Lerner-Geva L, Halevy A et al. The possible association between IVF and breast cancer incidence. Ann. Surg. Oncol. 15(4), 1048–1055 (2008).
   PubMed Web of Science ®Google Scholar
• Källén B, Finnström O, Lindam A, Nilsson E, Nygren KG, Olausson PO. Malignancies among women who gave birth after in vitro fertilization. Hum. Reprod. 26(1), 253–258 (2011).
   PubMed Web of Science ®Google Scholar
• Zreik TG, Mazloom A, Chen Y et al. Fertility drugs and the risk of breast cancer: a meta-analysis and review. Breast Cancer Res. Treat. 124(1), 13–26 (2010).
   PubMed Web of Science ®Google Scholar
• GoldsteinSR, SiddhantiS, CiacciaAV, PlouffeL Jr. A pharmacological review of selective oestrogen receptor modulators. Hum. Reprod. Update 6(3), 212–224 (2000).
   PubMed Web of Science ®Google Scholar
• Sovino H, Sir-Petermann T, Devoto L. Clomiphene citrate and ovulation induction. Reprod. Biomed. Online 4(3), 303–310 (2002).
   PubMedGoogle Scholar
• Henderson BE, Ross RK, Judd HL, Krailo MD, Pike MC. Do regular ovulatory cycles increase breast cancer risk? Cancer 56(5), 1206–1208 (1985).
   PubMed Web of Science ®Google Scholar
• Cowan LD, Gordis L, Tonascia JA, Jones GS. Breast cancer incidence in women with a history of progesterone deficiency. Am. J. Epidemiol. 114(2), 209–217 (1981).
   PubMed Web of Science ®Google Scholar
• Bolton PM. Bilateral breast cancer associated with clomiphene. Lancet 2(8049), 1176 (1977).
   PubMedGoogle Scholar
• Richards JF, Griffith DR. Effect of cis-and trans-clomiphene on mammary gland development in the rat. Fertil. Steril. 25(1), 74–78 (1974).
   PubMed Web of Science ®Google Scholar
• Sutherland RL, Watts CK, Hall RE, Ruenitz PC. Mechanisms of growth inhibition by nonsteroidal antioestrogens in human breast cancer cells. J. Steroid Biochem. 27(4–6), 891–897 (1987).
   PubMedGoogle Scholar
• Murphy LC, Sutherland RL. Antitumor activity of clomiphene analogs in vitro: relationship to affinity for the estrogen receptor and another high affinity antiestrogen-binding site. J. Clin. Endocrinol. Metab. 57(2), 373–379 (1983).
   PubMed Web of Science ®Google Scholar
• Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90(18), 1371–1388 (1998).
   PubMed Web of Science ®Google Scholar
• Lerner LJ, Jordan VC. Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture. Cancer Res. 50(14), 4177–4189 (1990).
   PubMed Web of Science ®Google Scholar
• Hecker E, Vegh I, Levy CM et al. Clinical trial of clomiphene in advanced breast cancer. Eur. J. Cancer 10(11), 747–749 (1974).
   PubMed Web of Science ®Google Scholar
• Coulam CB, Annegers JF, Kranz JS. Chronic anovulation syndrome and associated neoplasia. Obstet. Gynecol. 61(4), 403–407 (1983).
   PubMed Web of Science ®Google Scholar
• Ron E, Lunenfeld B, Menczer J et al. Cancer incidence in a cohort of infertile women. Am. J. Epidemiol. 125(5), 780–790 (1987).
   PubMed Web of Science ®Google Scholar
• Gammon MD, Thompson WD. Infertility and breast cancer: a population-based case–control study. Am. J. Epidemiol. 132(4), 708–716 (1990).
   PubMed Web of Science ®Google Scholar
• Brinton LA, Melton LJ 3rd, Malkasian GD Jr, Bond A, Hoover R. Cancer risk after evaluation for infertility. Am. J. Epidemiol. 129(4), 712–722 (1989).
   PubMed Web of Science ®Google Scholar
• Weiss HA, Troisi R, Rossing MA et al. Fertility problems and breast cancer risk in young women: a case–control study in the United States. Cancer Causes Control 9(3), 331–339 (1998).
   PubMed Web of Science ®Google Scholar
• Gips H, Hormel P, Hinz V. Ovarian stimulation in assisted reproduction. Andrologia 28(Suppl. 1), 3–7 (1996).
   PubMedGoogle Scholar
• Diedrich K, Felberbaum R. New approaches to ovarian stimulation. Hum. Reprod. 13(Suppl. 3), 1–13; discussion 14 (1998).
   PubMed Web of Science ®Google Scholar
• Leibowitz D, Hoffman J. Fertility drug therapies: past, present, and future. J. Obstet. Gynecol. Neonatal Nurs. 29(2), 201–210 (2000).
   PubMedGoogle Scholar
• Holzer H, Casper R, Tulandi T. A new era in ovulation induction. Fertil. Steril. 85(2), 277–284 (2006).
   PubMed Web of Science ®Google Scholar
• Jennings JC, Moreland K, Peterson CM. In vitro fertilisation. A review of drug therapy and clinical management. Drugs 52(3), 313–343 (1996).
   PubMed Web of Science ®Google Scholar
• Check JH, Slovis B. Choosing the right stimulation protocol for in vitro fertilization-embryo transfer in poor, normal, and hyper-responders. Clin. Exp. Obstet. Gynecol. 38(4), 313–317 (2011).
   PubMed Web of Science ®Google Scholar
• Zarek SM, Muasher SJ. Mild/minimal stimulation for in vitro fertilization: an old idea that needs to be revisited. Fertil. Steril. 95(8), 2449–2455 (2011).
   PubMed Web of Science ®Google Scholar
• Oehninger S. Ovulation induction in IVF. Minerva Ginecol. 63(2), 137–156 (2011).
   PubMedGoogle Scholar
• Al-Inany HG, Youssef MA, Aboulghar M et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst. Rev. 5, CD001750 (2011).
   PubMed Web of Science ®Google Scholar
• Kolibianakis EM, Tarlatzis B, Devroey P. GnRH antagonists in IVF. Reprod. Biomed. Online 10(6), 705–712 (2005).
   PubMed Web of Science ®Google Scholar
• Venn A, Hemminki E, Watson L, Bruinsma F, Healy D. Mortality in a cohort of IVF patients. Hum. Reprod. 16(12), 2691–2696 (2001).
   PubMed Web of Science ®Google Scholar
• Källén B, Finnström O, Nygren KG, Otterblad Olausson P, Wennerholm UB. In vitro fertilisation in Sweden: obstetric characteristics, maternal morbidity and mortality. BJOG 112(11), 1529–1535 (2005).
   PubMed Web of Science ®Google Scholar
• Impicciatore GG, Tiboni GM. Ovulation inducing agents and cancer risk: review of literature. Curr. Drug Saf. 6(4), 250–258 (2011).
   PubMedGoogle Scholar
• Cetin I, Cozzi V, Antonazzo P. Infertility as a cancer risk factor – a review. Placenta 29(Suppl. B), 169–177 (2008).
   PubMedGoogle Scholar
• Brinton LA, Sahasrabuddhe VV, Scoccia B. Fertility drugs and the risk of breast and gynecologic cancers. Semin. Reprod. Med. 30(2), 131–145 (2012).
   PubMed Web of Science ®Google Scholar
• Papanikolaou EG, Polyzos NP, Humaidan P et al. Aromatase inhibitors in stimulated IVF cycles. Reprod. Biol. Endocrinol. 9, 85 (2011).
   PubMedGoogle Scholar
• Fouda UM, Sayed AM. Extended letrozole regimen versus clomiphene citrate for superovulation in patients with unexplained infertility undergoing intrauterine insemination: a randomized controlled trial. Reprod. Biol. Endocrinol. 9, 84 (2011).
   PubMed Web of Science ®Google Scholar
• Casper RF. Aromatase inhibitors in ovarian stimulation. J. Steroid Biochem. Mol. Biol. 106(1–5), 71–75 (2007).
   PubMed Web of Science ®Google Scholar